Pustular eruption after biosimilar rituximab infusion: report of acute generalized exanthematous pustulosis in two patients with pemphigus
- 22 June 2021
- journal article
- letter
- Published by Wiley in International Journal of Dermatology
- Vol. 61 (1) , E14-E17
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Are biosimilars for pemphigus safe?Clinical and Experimental Dermatology, 2021
- Acute generalized exanthematous pustulosis with a focus on hydroxychloroquine: A 10-year experience in a skin hospitalInternational Immunopharmacology, 2020
- Iranian guideline for rituximab therapy in pemphigus patientsDermatologic Therapy, 2019
- Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational studyJournal of Dermatological Treatment, 2019
- Rituximab and Cytokine Release SyndromeCase Reports in Oncology, 2012
- Increased circulating Th17 frequencies and serum IL‐22 levels in patients with acute generalized exanthematous pustulosisJournal of the European Academy of Dermatology and Venereology, 2011
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008